[HTML][HTML] Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

JL Babitt, MF Eisenga, VH Haase, AV Kshirsagar… - Kidney international, 2021 - Elsevier
In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and
associated with significant adverse consequences. In 2012, Kidney Disease: Improving …

Current status of renal anemia pharmacotherapy—what can we offer today

B Borawski, JS Malyszko, M Kwiatkowska… - Journal of Clinical …, 2021 - mdpi.com
Chronic kidney disease (CKD) is one of the fastest-growing major causes of death
internationally. Better treatment of CKD and its complications is crucial to reverse this …

Challenging patient phenotypes in the management of anaemia of chronic kidney disease

S Pramod, DS Goldfarb - International Journal of Clinical …, 2021 - Wiley Online Library
Background Chronic kidney disease (CKD) is often complicated by anaemia, which is
associated with disease progression and increased hospital visits, decreased quality of life …

A nurse prescriber‐led protocol for anaemia management in established haemodialysis patients: A retrospective study

S George, M McCann - Journal of clinical nursing, 2020 - Wiley Online Library
Aim and objective To evaluate the impact of a nurse prescriber‐led protocol compared to a
traditional physician‐led nonprotocol‐based approach had on maintaining targeted …

[HTML][HTML] Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience

II Kacarska-Fotevska, N Volckova, K Ilievska… - Medical …, 2020 - ncbi.nlm.nih.gov
Aim: To evaluate safety and efficacy of methoxy polyethylene glycol-epoetin beta as
continuous erythropoietin receptor activator (CERA) in maintenance of haemoglobin (Hb) …

[HTML][HTML] Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian …

I Kacarska-Fotevska, N Volckova, K Ilievska… - Croatian Medical …, 2019 - ncbi.nlm.nih.gov
issued a Public Statement to physicians to use ESAs strictly in accordance with their
approved Summary of Product Characteristics regarding the indications and dosing …

Prevalence, risk factors, and prescribing trends in chronic renal failure in the Indian population

J Suthar, RD Patel, S Desai - Journal of Pharmacology and …, 2021 - journals.sagepub.com
Objective: To estimate the prevalence of Chronic renal failure (CRF) in the Indian
subcontinent and to identify risk factors and treatment regimens for CRF. Methods: A …

Effects of novel anemia nurse manager program on hemodialysis: a retrospective study from Qatar

A Hamad, H Ezzat, TA Latif Ghonimi, R Ibrahim… - Qatar Medical …, 2021 - qscience.com
Introduction: Anemia management in dialysis is challenging. Keeping hemoglobin levels
within a tight range is difficult. A new program (anemia nurse manager [ANM]) was started …

Evaluating the utilisation and expenditure patterns of erythropoietin stimulating agents and immunosuppressants in Australian chronic kidney disease patients

IK Stanley, KL Schultz, KM Gardiner… - Journal of …, 2021 - academic.oup.com
Objectives This study aimed to characterise utilisation and expenditure patterns associated
with erythropoietin stimulating agents (ESAs)(darbepoetin alfa, epoetin alfa, epoetin beta …